Details
Stereochemistry | RACEMIC |
Molecular Formula | C28H31NO5 |
Molecular Weight | 461.5494 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)C(=O)OC2=C(OC(=O)C3=CC=C(C)C=C3)C=C(C=C2)C(O)CNC(C)(C)C
InChI
InChIKey=FZGVEKPRDOIXJY-UHFFFAOYSA-N
InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3
Molecular Formula | C28H31NO5 |
Molecular Weight | 461.5494 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Bitolterol is a beta 2-adrenergic agonist. Since it in itself is biologically inactive, bitolterol is considered a pro-drug. When administered it is activated within the lung by esterase hydrolysis to the active compound colterol catecholamine N-t-butyl-arterenol. Bitolterol was marked under the name tornalate and was indicated to prevent and treat of reversible bronchospasm associated with asthma or chronic obstructive pulmonary diseases. But that drug was withdrawn from the market by Elan Pharmaceuticals in 2001.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3278878 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TORNALATE Approved UseUnknown Launch Date1984 |
|||
Primary | TORNALATE Approved UseUnknown Launch Date1984 |
PubMed
Title | Date | PubMed |
---|---|---|
Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. | 1988 Jan |
|
Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm. | 1995 May-Jun |
|
Accuracy of Veterans Affairs databases for diagnoses of chronic diseases. | 2009 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/bitolterol-mesylate.html
Acute Bronchospasm: adults and children older than 12 yr of age: oral inhalation 2 inhalations at interval of 1 to 3 min, followed by third inhalation if necessary.
Prevention of Bronchospasm: adults and children older than 12 yr of age: oral inhalation 2 inhalations every 8 h, not to exceed 3 inhalations every 6 h or 2 inhalations every 4 h.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:30:13 GMT 2023
by
admin
on
Fri Dec 15 16:30:13 GMT 2023
|
Record UNII |
9KY0QXD6LI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
||
|
WHO-VATC |
QR03AC17
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
||
|
LIVERTOX |
112
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
||
|
WHO-ATC |
R03AC17
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m2578
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
384
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
C65267
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
35330
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
SUB05860MIG
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
DTXSID1022683
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
3855
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
19499
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | RxNorm | ||
|
30392-40-6
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201295
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
C011685
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
DB00901
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
9KY0QXD6LI
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
BITOLTEROL
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
100000086343
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
3133
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY | |||
|
Bitolterol
Created by
admin on Fri Dec 15 16:30:13 GMT 2023 , Edited by admin on Fri Dec 15 16:30:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
TARGET -> AGONIST |
SHORT-ACTING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |